Related Experiment Video
Updated: Dec 18, 2025

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the
Kevin T Bain1,2, Calvin H Knowlton3, Adriana Matos1
1Department of Applied Precision Pharmacotherapy Institute, Tabula Rasa HealthCare, Moorestown, NJ 08057, USA.
Abstract:
Aim: Estimate cost avoidance of pharmacist recommendations for participants enrolled in the Program of All-inclusive Care for the Elderly. Materials & methods: Convenience sample of 200 pharmacogenomics consultations from the PHARM-GENOME-PACE study. Genetic variants, drug-gene interactions, drug-drug-gene interactions and phenoconversions were interrogated. Cost avoidance was estimated and adjusted for inflation. Results: In total, 165 participants had at least one actionable drug-gene pair totaling 429 drug-gene pairs, of which 158 (36.8%) were clinically actionable. Most (70.5%) pharmacists' recommendations were accepted. Estimated cost avoidance was $233,945 when all recommendations were included but conservatively $162,031 based on acceptance rates. Overall mean cost avoidance per actionable drug-gene pair was $1063 or $1983 per participant. Conclusion: Pharmacist-led pharmacogenomics services added to the traditional medication review can avoid substantial costs for payers. Clinical trial registration number: NCT03257605.
Related Concept Videos
Preventive Healthcare Services
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

